Jessica Gill1, Lawrence Latour2, Ramon Diaz-Arrastia2, Vida Motamedi2, Christine Turtzo2, Pashtun Shahim2, Stefania Mondello2, Christina DeVoto2, Eliseo Veras2, David Hanlon2, Linan Song2, Andreas Jeromin2. 1. From the National Institutes of Health (J.G., V.M., C.D.), National Institute of Nursing Research, the Center for Neuroscience and Regenerative Medicine (J.G., P.S.), Uniformed Services University of the Health Sciences, Biomarker Core, and the National Institutes of Health (L.L., C.T.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; the Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia, PA; the Department of Biomedical and Dental Sciences and Morphofunctional Imaging (S.M.), University of Messina, Italy; and the Quanterix Corporation (E.V., D.H., L.S., A.J.), Lexington, MA. gillj@mail.nih.gov. 2. From the National Institutes of Health (J.G., V.M., C.D.), National Institute of Nursing Research, the Center for Neuroscience and Regenerative Medicine (J.G., P.S.), Uniformed Services University of the Health Sciences, Biomarker Core, and the National Institutes of Health (L.L., C.T.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; the Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia, PA; the Department of Biomedical and Dental Sciences and Morphofunctional Imaging (S.M.), University of Messina, Italy; and the Quanterix Corporation (E.V., D.H., L.S., A.J.), Lexington, MA.
Abstract
OBJECTIVES: To determine whether a panel of blood-based biomarkers can discriminate between patients with suspected mild traumatic brain injury (mTBI) with and without neuroimaging findings (CT and MRI). METHODS: Study participants presented to the emergency department with suspected mTBI (n = 277) with a CT and MRI scan and healthy controls (n = 49). Plasma concentrations of tau, glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1, and neurofilament light chain (NFL) were measured using the single-molecule array technology. RESULTS: Concentrations of GFAP, tau, and NFL were higher in patients with mTBI, compared with those of controls (p's < 0.01). GFAP yielded an area under the curve (AUC) of 0.93 (95% confidence interval [CI] 0.90-0.96), confirming its discriminatory power for distinguishing mTBI from controls. Levels of GFAP, tau, and NFL were higher in patients with trauma-related intracranial findings on CT compared with those with normal CT, with the only significant predictor being GFAP (AUC 0.77, 95% CI 0.70-0.84). Among patients with mTBI, tau, NFL, and GFAP differentiated subjects with and without MRI abnormalities with an AUC of 0.83, with GFAP being the strongest predictor. Combining tau, NFL, and GFAP showed a good discriminatory power (AUC 0.80, 95% CI 0.69-0.90) for detecting MRI abnormalities, even in patients with mTBI with a normal CT. CONCLUSION: Our study confirms GFAP as a promising marker of brain injury in patients with acute mTBI. A combination of various biomarkers linked to different pathophysiologic mechanisms increases diagnostic subgroup accuracy. This multimarker strategy may guide medical decision making, facilitate the use of MRI scanning, and prove valuable in the stratification of patients with brain injuries in future clinical trials. CLASSIFICATION OF EVIDENCE: Class I evidence that blood concentrations of GFAP, tau, and NFL discriminate patients with mTBI with and without neuroimaging findings.
OBJECTIVES: To determine whether a panel of blood-based biomarkers can discriminate between patients with suspected mild traumatic brain injury (mTBI) with and without neuroimaging findings (CT and MRI). METHODS: Study participants presented to the emergency department with suspected mTBI (n = 277) with a CT and MRI scan and healthy controls (n = 49). Plasma concentrations of tau, glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1, and neurofilament light chain (NFL) were measured using the single-molecule array technology. RESULTS: Concentrations of GFAP, tau, and NFL were higher in patients with mTBI, compared with those of controls (p's < 0.01). GFAP yielded an area under the curve (AUC) of 0.93 (95% confidence interval [CI] 0.90-0.96), confirming its discriminatory power for distinguishing mTBI from controls. Levels of GFAP, tau, and NFL were higher in patients with trauma-related intracranial findings on CT compared with those with normal CT, with the only significant predictor being GFAP (AUC 0.77, 95% CI 0.70-0.84). Among patients with mTBI, tau, NFL, and GFAP differentiated subjects with and without MRI abnormalities with an AUC of 0.83, with GFAP being the strongest predictor. Combining tau, NFL, and GFAP showed a good discriminatory power (AUC 0.80, 95% CI 0.69-0.90) for detecting MRI abnormalities, even in patients with mTBI with a normal CT. CONCLUSION: Our study confirms GFAP as a promising marker of brain injury in patients with acute mTBI. A combination of various biomarkers linked to different pathophysiologic mechanisms increases diagnostic subgroup accuracy. This multimarker strategy may guide medical decision making, facilitate the use of MRI scanning, and prove valuable in the stratification of patients with brain injuries in future clinical trials. CLASSIFICATION OF EVIDENCE: Class I evidence that blood concentrations of GFAP, tau, and NFL discriminate patients with mTBI with and without neuroimaging findings.
Authors: Franck Amyot; David B Arciniegas; Michael P Brazaitis; Kenneth C Curley; Ramon Diaz-Arrastia; Amir Gandjbakhche; Peter Herscovitch; Sidney R Hinds; Geoffrey T Manley; Anthony Pacifico; Alexander Razumovsky; Jason Riley; Wanda Salzer; Robert Shih; James G Smirniotopoulos; Derek Stocker Journal: J Neurotrauma Date: 2015-09-30 Impact factor: 5.269
Authors: David O Okonkwo; John K Yue; Ava M Puccio; David M Panczykowski; Tomoo Inoue; Paul J McMahon; Marco D Sorani; Esther L Yuh; Hester F Lingsma; Andrew I R Maas; Alex B Valadka; Geoffrey T Manley Journal: J Neurotrauma Date: 2013-08-01 Impact factor: 5.269
Authors: Ramon Diaz-Arrastia; Kevin K W Wang; Linda Papa; Marco D Sorani; John K Yue; Ava M Puccio; Paul J McMahon; Tomoo Inoue; Esther L Yuh; Hester F Lingsma; Andrew I R Maas; Alex B Valadka; David O Okonkwo; Geoffrey T Manley Journal: J Neurotrauma Date: 2013-10-09 Impact factor: 5.269
Authors: Frederick K Korley; Gabor D Kelen; Courtney M Jones; Ramon Diaz-Arrastia Journal: J Head Trauma Rehabil Date: 2016 Nov/Dec Impact factor: 2.710
Authors: Robert D Welch; Syed I Ayaz; Lawrence M Lewis; Johan Unden; James Y Chen; Valerie H Mika; Ben Saville; Joseph A Tyndall; Marshall Nash; Andras Buki; Pal Barzo; Dallas Hack; Frank C Tortella; Kara Schmid; Ronald L Hayes; Arastoo Vossough; Stephen T Sweriduk; Jeffrey J Bazarian Journal: J Neurotrauma Date: 2015-12-18 Impact factor: 5.269
Authors: W Frank Peacock; Timothy E Van Meter; Nazanin Mirshahi; Kyle Ferber; Robert Gerwien; Vani Rao; Haris Iqbal Sair; Ramon Diaz-Arrastia; Frederick K Korley Journal: Front Neurol Date: 2017-11-30 Impact factor: 4.003
Authors: Linda Papa; Gretchen M Brophy; Robert D Welch; Lawrence M Lewis; Carolina F Braga; Ciara N Tan; Neema J Ameli; Marco A Lopez; Crystal A Haeussler; Diego I Mendez Giordano; Salvatore Silvestri; Philip Giordano; Kurt D Weber; Crystal Hill-Pryor; Dallas C Hack Journal: JAMA Neurol Date: 2016-05-01 Impact factor: 18.302
Authors: Samuel W Remedios; Snehashis Roy; Camilo Bermudez; Mayur B Patel; John A Butman; Bennett A Landman; Dzung L Pham Journal: Med Phys Date: 2019-11-19 Impact factor: 4.071
Authors: Lisa Christine Turtzo; Neekita Jikaria; Martin R Cota; Joshua P Williford; Victoria Uche; Tara Davis; Judy MacLaren; Anita D Moses; Gunjan Parikh; Marcelo A Castro; Dzung L Pham; John A Butman; Lawrence L Latour Journal: Brain Commun Date: 2020-09-09
Authors: Grant C O'Connell; Megan L Alder; Christine G Smothers; Carolyn H Still; Allison R Webel; Shirley M Moore Journal: Neurol Res Date: 2020-02-12 Impact factor: 2.448
Authors: David F Tate; Emily L Dennis; John T Adams; Maheen M Adamson; Heather G Belanger; Erin D Bigler; Heather C Bouchard; Alexandra L Clark; Lisa M Delano-Wood; Seth G Disner; Blessen C Eapen; Carol E Franz; Elbert Geuze; Naomi J Goodrich-Hunsaker; Kihwan Han; Jasmeet P Hayes; Sidney R Hinds; Cooper B Hodges; Elizabeth S Hovenden; Andrei Irimia; Kimbra Kenney; Inga K Koerte; William S Kremen; Harvey S Levin; Hannah M Lindsey; Rajendra A Morey; Mary R Newsome; John Ollinger; Mary Jo Pugh; Randall S Scheibel; Martha E Shenton; Danielle R Sullivan; Brian A Taylor; Maya Troyanskaya; Carmen Velez; Benjamin Sc Wade; Xin Wang; Ashley L Ware; Ross Zafonte; Paul M Thompson; Elisabeth A Wilde Journal: Brain Imaging Behav Date: 2021-01-07 Impact factor: 3.978
Authors: Angela M Boutté; Vivian Hook; Bharani Thangavelu; George Anis Sarkis; Brittany N Abbatiello; Gregory Hook; J Steven Jacobsen; Claudia S Robertson; Janice Gilsdorf; Zhihui Yang; Kevin K W Wang; Deborah A Shear Journal: J Neurotrauma Date: 2020-04-02 Impact factor: 5.269
Authors: Pashtun Shahim; Adam Politis; Andre van der Merwe; Brian Moore; Vindhya Ekanayake; Sara M Lippa; Yi-Yu Chou; Dzung L Pham; John A Butman; Ramon Diaz-Arrastia; Henrik Zetterberg; Kaj Blennow; Jessica M Gill; David L Brody; Leighton Chan Journal: Neurology Date: 2020-07-08 Impact factor: 9.910
Authors: Pashtun Shahim; Adam Politis; Andre van der Merwe; Brian Moore; Yi-Yu Chou; Dzung L Pham; John A Butman; Ramon Diaz-Arrastia; Jessica M Gill; David L Brody; Henrik Zetterberg; Kaj Blennow; Leighton Chan Journal: Neurology Date: 2020-07-08 Impact factor: 9.910